SERTAD3 Inhibitors

Chemical inhibitors of SERTAD3 can exert their inhibitory effects through various mechanisms, each related to the protein's role in cell cycle regulation. Alisertib, for example, targets Aurora A kinase, a key enzyme necessary for proper mitotic entry, where SERTAD3 is known to play a pivotal role. By inhibiting Aurora A kinase, alisertib disrupts the events required for chromosomal alignment and segregation, processes in which SERTAD3 is implicated. Similarly, the chemical palbociclib, which inhibits CDK4/6, prevents the phosphorylation of SERTAD3. Since phosphorylation is a post-translational modification that can regulate protein function, the activity of SERTAD3 as a cell cycle promoter is reduced without this modification. Additionally, roscovitine and dinaciclib contribute to the inhibition of SERTAD3 by inhibiting cyclin-dependent kinases. These kinases are responsible for the phosphorylation state of SERTAD3, which is crucial for its activity in driving the cell cycle forward. Olomoucine follows a similar pattern by inhibiting CDK1, CDK2, and CDK5, thereby potentially reducing the phosphorylation state and subsequent activity of SERTAD3.

Furthermore, the chemical thiazovivin, which inhibits ROCK, can impact the dynamics of the cell cycle and thus the function of SERTAD3 in regulating cell cycle progression. Y-27632 also inhibits ROCK, affecting cell shape and division, which are processes where SERTAD3 is involved. The JNK inhibitor SP600125 can alter pathways that regulate the cell cycle, thereby influencing the activity of SERTAD3. Inhibitors like AZD7762 and PF-477736, which target checkpoint kinases CHK1/2, may disrupt the proper functioning of cell cycle checkpoints. Since SERTAD3 is known to be involved in these checkpoints, inhibiting CHK1/2 indirectly affects SERTAD3's participation in checkpoint control. LY2603618, another CHK1 inhibitor, alters the cell cycle progression at the checkpoint level, thereby inhibiting the role SERTAD3 plays within this critical cell cycle juncture.